908 Devices Inc. (MASS)
NASDAQ: MASS · IEX Real-Time Price · USD
6.85
-0.03 (-0.44%)
At close: May 17, 2024, 4:00 PM
6.94
+0.09 (1.31%)
After-hours: May 17, 2024, 6:53 PM EDT
908 Devices Revenue
908 Devices had revenue of $50.73M in the twelve months ending March 31, 2024, with 5.62% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $9.99M with 5.31% year-over-year growth. In the year 2023, 908 Devices had annual revenue of $50.23M with 7.21% growth.
Revenue (ttm)
$50.73M
Revenue Growth
+5.62%
P/S Ratio
4.64
Revenue / Employee
$220,578
Employees
230
Market Cap
235.19M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 50.23M | 3.38M | 7.21% |
Dec 31, 2022 | 46.85M | 4.65M | 11.01% |
Dec 31, 2021 | 42.21M | 15.31M | 56.93% |
Dec 31, 2020 | 26.89M | 8.92M | 49.64% |
Dec 31, 2019 | 17.97M | -4.08M | -18.51% |
Dec 31, 2018 | 22.05M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AirSculpt Technologies | 197.72M |
Akebia Therapeutics | 187.23M |
G1 Therapeutics | 84.04M |
OptimizeRx | 78.21M |
uniQure | 19.00M |
Ovid Therapeutics | 473.54K |
MASS News
- 3 days ago - 908 Devices to Participate in Upcoming Investor Conferences - Business Wire
- 18 days ago - 908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook - Business Wire
- 18 days ago - 908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering - Business Wire
- 25 days ago - 908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024 - Business Wire
- 2 months ago - 908 Devices Trace Chemical Identification Technology Adopted by European Agencies - Business Wire
- 2 months ago - 908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook - Business Wire
- 2 months ago - 908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares' Fully Integrated Cell Therapy Manufacturing Platform - Business Wire
- 3 months ago - 908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 - Business Wire